Skip to content

Released May 11, 2026, before the open

10-Q filed May 11, 2026, 41 days after period end · 0001628280-26-033429

Q1 2026 · 10-Q
Revenue—
Net Income-$56.21MN/M vs Q1 2025N/M vs Q4 2025
EPS Diluted-$0.93N/M vs Q1 2025no prior Q4 2025 on file
Operating Income-$60,242,000N/M
Operating Cash Flow-$37,508,000N/M
Free Cash Flowderived-$37,568,000N/M

What the release said

The release

Same quarter

MetricQ1 2026Q1 2025Q1 2024Q1 2023
Net Income-$56.21M-$36.85M-$12.51M-$7.41M
EPS Diluted-$0.93-$0.68-$18.94—

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Bicara Therapeutics Inc. · CIK 2023658 · Engraved from SEC EDGAR